It is known that phosphoinositide-specific phospholipases g1 (PLCg1) can trigger several signalling pathways to regulate cell proliferation, differentiation, and metastasis. However, whether this kinase is highly expressive and active in human gastric adenocarcinomas, and whether it can play an important role in the development of the cancer, have not yet been investigated. The aim of the study was to investigate the expression of PLCg1 in human gastric adenocarcinoma, while the question of whether PLCg1 can be activated through protein kinase B (Akt) signalling pathways to regulate cell migration was further explored using human gastric adenocarcinoma BGC-823 cell line. The expression of PLCg1 in human adenocarcinoma was detected using immunohistochemical staining. The BGC-823 cells were cultured and treated with inhibitors or transfected with plasmid construction. The cell migration of BGC-823 cells was measured with wound healing assay, cell migration assay, and the ruffling assay. The expression levels of PLCg1 and its related signal molecules in BGC-823 cells were assessed using Western blot analysis or gelatine zymography assay. PLCg1 was highly expressed in human gastric adenocarcinomas, especially in the region with lymph node metastasis. It was shown that migration of BGC-823 cells in vitro depends on PLCg1 activation. This activation is mediated through Akt, an upstream of PLCg1 that triggers the PLCg1/extracellular signal-regulated kinase (ERK)/matrix metalloproteinase (MMP) pathway in BGC-823 cells. PLCg1 activities play an important role in the metastasis of gastric adenocarcinoma, and may serve as a potential therapeutic target in this type of cancer.
Introduction
It has been reported that approximately 90% of mortality from cancers arises from the metastatic spread of primary tumors to distant sites, including gastric adenocarcinoma [1] . Metastasis usually includes a complex series of steps in which cancer cells leave the original tumor site and migrate to other parts of the body via the bloodstream, the lymphatic system, or by direct extension. Inhibition of any one metastatic step -such as migration or invasion -could prevent tumor dissemination [1, 2] . Recent studies suggest targeted molecular therapy as a potential solution in cancer therapy, because it is more effective than current treatments and less harmful to normal cells [3] . The regulation of certain key signalling molecules has been identified as crucial in tumor metastasis; the molecules involved in cell migration may thus serve as molecular targets for the treatment of tumor metastasis [4, 5] . Several lines of evidence indicate that phosphoinositide-specific phospholipase g (PLCg) is one of key signalling molecules that regulates tumor metastasis [6] [7] [8] [9] . PLCg has two isoforms, PLCg1 and PLCg2 [6, 7] . Activation of PLCg may occur in response to either integrin receptors or growth factor-dependent pathways -including epidermal growth factor (EGF) -and induces hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) to form the second messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), which in turn activate a number of signalling pathways to regulate cell metabolism and cell metastasis [6] [7] [8] [9] . For example, activated PLCg has been thought to play a critical role in both cytoskeletal changes and in the migration associated with the metastatic process in cancer cells [8] . Preventing the activation of the PLCg signalling pathway could limit the metastatic potential of breast and prostate cancers [9] . Both stable and inducible PLCg1 downregulation resulted in an almost complete inhibition of breast cancer-derived experimental lung metastasis formation [10] . Thus, PLCg plays an important role in some types of metastatic cancer. However, it is not clear whether the downregulation of PLCg1 may play a similar role in human gastric adenocarcinoma, compared to other types of cancers, and the possible effects of its inhibition have yet not been explored.
In addition to PLCg, protein kinase B (PKB/Akt), another well-known regulator of tumor metastasis, has been shown to modulate the same physiological process in some types of cancer [11, 12] . Both PLCg and Akt are known to be involved in the regulation of the growth and migration of MDA-MB-468 breast cancer and SW480 colon cancer cells [11] . The interaction between PLCg and Akt was found to regulate the G2/M transition in MDA-MB-231 breast cancer cells [12] . Therefore, exploring the relationship of PLCg and Akt in cancer metastasis will greatly assist in understanding the regulatory mechanisms of PLCg1 underpinning cell migration.
In this project, we aimed to study the expression level of PLCg1 in human gastric adenocarcinoma and normal gastric mucosa tissue, and to further investigate the molecular mechanisms of the PLCg1 activity associated with Akt that underpins cell migration in the human gastric adenocarcinoma cell line, BGC--823. The results of this project are intended to provide additional evidence that PLCg may be a potential target for cancer treatment, and especially for the treatment of gastric adenocarcinoma.
Material and methods
Reagents and antibodies. Antibodies against PLCg1, p-PL--Cg1 (Y783), p-PLCg1 (S1248), Akt, p-Akt (S473), Extracel- Cell culture. The human gastric cancer cell line, BGC-823, was obtained from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Shanghai, China, and was maintained in RPMI1640 medium supplemented with 10% foetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin, at 37°C in a water-saturated atmosphere of 5% CO2.
Plasmid construction and transfection. Rat PLCg1 cDNA was N-terminally tagged with the HA sequence and subcloned into pRK5-HA (pRK5-HA/PLCg1). The Y783 and S1248 mutations were obtained by PCR (PLCg1 Y783A, 5'CAACCCTGGTTTCGCTGTGGAGGCCAACCCTAT-GC (forward primer), 5'TTGGCCTCCACAGCGAAAC-CAGGGTTGCGGCC (reverse primer); PLCg1 S1248A, 5'CCGGGAAGGGGCCTTTGAAGCCAGATACCAG-CAG (forward primer), 5' CTGGCTTCAAAGGCCCCT-TCCCGGGCCCG (reverse primer). The ShPLCg1 vector (primer: 5'CCGGCCAGATCAGTAACCCTGAATTC-TCGAGAATTCAGGGTTACTGATCTGTTTTTG3') was purchased from Gene Chem (Shanghai, China). The different expression vectors of PLCg1 and myc-Akt were transfected into BGC-823 cells using Lipofectamine 2000, according to the manufacturer's procedure (Invitrogen, Carlsbad, CA, USA). Briefly, BGC-823 cells were cultured in a 60-mm dish for 20-24 h until they reached 60-70% confluence. The plasmid-containing buffer was then added and left for 36 h, and was followed by the various experimental procedures in which the expression level of PLCg1 and Akt were detected with Western blot analysis, prior to the other experiments.
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Luhua Zhuang et al. Wound healing assay. The assay was conducted according to published protocol [13] . Briefly, a total of 2 × 10 6 cells were seeded onto two six-well plates and allowed to reach full confluence. Two centrelines were marked on the upside of each well along its horizontal axis, to designate the loci at which images would be acquired at each time point. Vertical linear scratches were introduced into the cell monolayers using a 10 μL sterile pipette tip. Each well received 2 scratches. Culture plates were washed with PBS and incubated with PLCg inhibitor U73122, which was followed by EGF treatment in serum-free medium. Images at 40 × magnification were acquired at 0, 7, 24, and 48 h after scratching at each intersection of the scratch wound (vertical defect). For each time point, 4 measurements were taken per well in each of 3 wells, and the average of the horizontal width of the linear defect in pixels was calculated using the Image-Pro Plus 6.0 system. The mean percentage closure was calculated by compared with time 0.
Cell migration assay. Cell migration was performed in Transwell chambers (tissue culture treated, 6.5 mm diameter, 8 μm pores, Corning Inc., Corning, NY, USA) as described elsewhere [14] . Briefly, 2 × 10 4 cells in serum-free DMEM were placed into the upper chambers of Transwell inserts set within wells with 8 μm pore filters, and incubated at 37°C for 12 h. Cells on the upper surface of the chambers were then removed with cotton swabs. The migrated cells on the lower membrane surface were fixed in methanol and stained with 0.1% Giemsa stain. Eight microscope fields (× 200) from each Transwell chamber were randomly selected, and cells adhering to the undersurface of the filter were imaged and counted using an Olympus BX41 microscope equipped with a digital camera (Olympus, Tokyo, Japan).
Gelatine zymography assay. The assay was conducted according to published protocol [15] . Protein concentrations in the conditioned media were determined using the bicinchoninic acid method (BCA kit) (Pierce, Rockford, IL, USA). The conditioned media were mixed with an equal volume of 4 × sample buffer (200 mM Tris-HCl, 8% SDS, 0.4% bromophenol blue, 40% glycerol) and electrophoresed on 6% SDS polyacrylamide gels containing 1 mg/ml of gelatine (Bio Basic Inc., Markham, Ontario, Canada). The gels were then washed twice for 30 min in 2.5% Triton X-100 at room temperature, and incubated for 48 h at 37°C in incubation buffer (50 mM Tris-HCl (pH 7.5), 5 mM CaCl2, 150 mM NaCl, 1 μM ZnCl2, and 0.2% Brij35). Gels were then stained for 1 h with 0.25% (w/v) Coomassie brilliant blue R-250, and de-stained in de-staining buffer (10% acetic acid and 50% methanol).
Confocal microscopy and ruffling assay. The assay was conducted according to published protocol [10] . The cells were seeded on glass coverslips in 6-well plates and pretreated with U73122, followed by EGF treatment. The treated cells were rinsed with PBS once and fixed in 4% paraformaldehyde for 10 min, and then washed three times with PBS. After 5 min permeation with 0.5% Triton X-100, the cells were incubated with Rhodamine-conjugated Phalloidin (Cytoskeleton Inc., Denver, CO, USA) for 30 min at room temperature, before being stained with DAPI for 30 sec. Finally, the cells were observed and photographed using confocal microscopy.
Western blot analysis. The protein extracts were subjected to SDS-PAGE (8-10%) and transferred to nitrocellulose membrane for Western blot analysis [16] . The membrane was incubated at 4°C overnight with various antibodies as required, which was followed by the addition of the corresponding secondary antibody at room temperature for 1 to 2 h. An ECL kit was used to detect antibody reactivity (Pierce).
Immunohistochemical staining and analysis. The immunohistochemistry was performed as described previously [17, 18] . The tissue microarray was deparaffinised in xylene and rehydrated in graded alcohols and distilled water. Following antigen retrieval using the Citrate Buffer method -which can enhance the staining intensity of the antibodies by unmasking the antigens and epitopes in formalin-fixed and paraffin-embedded tissue sections -endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for 10 min at room temperature. This was followed by rehydration in PBS and incubation with 10% goat serum for 10 min to bind nonspecific antigens. As described in the manufacturer's instruction (MAIXIN.BIO, Fuzhou, China), the sections were incubated overnight at 4°C with PLCg1 (1:100 dilutions) primary antibody and subsequently with secondary antibody (1:400) for 60 min at room temperature. Diaminobenzidine (DAB) was used to visualize the immunohistochemical reaction, before counterstaining with haematoxylin. In the control sections, the specific primary antibody was omitted or replaced with non-immune serum or isotype-matched immunoglobulins. Photomicrographs were taken using an Olympus BX41 microscope equipped with a digital camera.
A semiquantitative scoring system based on staining intensity and the distribution of positive cells was used to evaluate PLCg1 expression [18, 19] . The intensity of PLCg1 staining ranged from 0 to 3 -i.e., negative (-), weak (+), moderate (++) , and strong (+++), and was performed using Image-Pro Plus 6.0 Software. Two pathologists were consulted for agreement and the scores were quantified by three independent observers using the criteria for statistical analysis detailed in Figure 1C .
Statistical analysis. The differences between the groups were examined for statistical significance using the c 2 test, Student's t-test, and one-way ANOVA using SPSS software. A value of p < 0.05 was considered significant.
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Results

PLCg1 is highly expressed in human gastric adenocarcinoma
Fresh human normal gastric mucosa tissue and gastric adenocarcinoma tissue were used for Western blot analysis of PLCg1. The results showed that PLCg1 expression was higher in human gastric adenocarcinoma than in normal gastric mucosa, while homogenously weak expression of PLCg1 was observed in normal gastric mucosa tissues ( Figure 1A) . Simultaneously, PLCg1 expression was higher in gastric ade- www.fhc.viamedica.pl nocarcinoma tissues with lymph node metastasis (N1, N2) than in gastric adenocarcinoma tissues lacking lymph node metastasis (N0) ( Figure 1A) .
Subsequently, PLCg1 expression was assessed immunohistochemically on a tissue microarray. The majority (86%) of gastric adenocarcinoma specimens (T2, T3, T4) showed a specific immune reactivity to PLCg1 ( Figure 1B and 1C, Table 1 , p < 0.01). PLCg1 expression was significantly higher in gastric adenocarcinoma specimens with regional lymph node metastasis (N1, N2) than in non-metastatic specimens (N0) ( Figure 1C , Table 1 , p < 0.05). These data indicate that PLCg1 expression is higher in gastric adenocarcinoma tissues than in normal gastric mucosa, and, specifically, in gastric adenocarcinoma tissues with regional lymph node metastasis.
The migration of gastric adenocarcinoma cells partly depends on PLCg1 activation
To investigate the role of PLCg1 in the migration of gastric adenocarcinoma cells, cells of the cultured gastric adenocarcinoma line BGC-823 were pretreated using PLCg1 inhibitor U73122 (5 μmol/L) for the indicated time in the presence or absence of EGF (20 ng/ml) [20, 21] . This was followed by a wound healing assay and Western blot analysis. The result of the wound healing assay showed that the addition of U73122 significantly suppressed the mean percentage closure of BGC-823 cells in the presence or absence of EGF treatment, compared with the untreated group, while the inhibitory effect of U73122 on the mean percentage closure of BGC-823 cells increased in a time-dependent manner (Figure 2A) .
Simultaneously, Western blot analysis showed that the addition of PLCg1 inhibitor U73122 reduced the phosphorylation level of PLCg1 at the Y783 site (p-PLCg1 (Y783)), which is essential for PLCg1 activation [3] , with a decrease in the expression level of MMP9 and MMP2 in the presence or absence of EGF treatment ( Figure 2B ).
Since several lines of evidence indicate that the PLCg1 substrate PtdIns(4, 5)P2 and the enzyme itself were involved in cytoskeletal rearrangement through the modulation of actin-binding proteins [22, 23] , we tested the effects of U73122 on actin cytoskeleton using confocal microscopy and a ruffling assay after rhodamine-conjugated phalloidin staining. The addition of U73122 led to a marked decrease in the number of membrane ruffles of BGC-823 cells in the presence or absence of EGF treatment ( Figure  2C) , with the reduction of actin cytoskeleton reorganization in cytoplasm ( Figure 2D , indicated as white arrows). Taken together, these data suggest that the migration of BGC-823 cells partly depends on PLCg1 activation.
Akt is involved in PLCg1-dependent migration of gastric adenocarcinoma cells
To confirm the role of Akt in PLCg1-dependent migration of gastric adenocarcinoma cells, BGC-823 cells were treated with an Akt inhibitor Triciribine (TCN) for the indicated time, and PLCg1 expression and activation were assessed by Western blot analysis.
The addition of TCN (10 μmol/L) significantly suppressed PLCg1 and Akt activation, with a slight downregulation of total PLCg1 expression ( Figure  3A) . Similar results were observed in BGC-823 cells with the transfection of the myc-Akt vector. Overexpression of Akt upregulated the expression level of PLCg1 and its activation (p-PLCg1 (Y783)), while the expression of p-PLCg1 (S1248) was also upregulated, albeit to a lower extent ( Figure 3B ). Simultaneously, overexpression of Akt upregulated the expression level of MMP2/9 ( Figure 3B ).
Interestingly, the phosphorylation level of ERK (p-ERK) also was upregulated in the BGC-823 cells transfected with overexpression of the Akt vector (Figure 3B). EGF treatment enhanced the effect of Akt on p-PLCg1 (Y783), p-PLCg1 (S1248), p-ERK, and MMP2/9 expression. Furthermore, only HA-PLCg1 A. Cells were treated with or without U73122 (5 μmol/L) for the indicated time in the presence or absence of EGF (20 ng/ml); this was followed by wound healing assays, as described in the Material and methods section (magnification × 40); B. Cells were pretreated with U73122 (5 μmol/L) for 2 h, and then treated with EGF (20 ng/ml) for 0.5 h. Protein expressions of p-PLCg1 (Y783), MMP2, MMP9, and b-actin were detected using Western blot analysis with the corresponding antibodies; C. Cells were pretreated with U73122 (5 μmol/L) for 2 h and then treated with EGF (20 ng/ml) for 1 h. The formation of membrane ruffles was then detected using confocal microscopy and ruffling assay following Rhodamine-conjugated Phalloidin staining, as described in the Material and methods section (magnification × 400, *p < 0.05, **p < 0.01, and ***p < 0.001); D. Cells were treated as in Figure 2C , and the effect of U73122 on actin cytoskeleton was observed using confocal microscopy following Rhodamine-conjugated Phalloidin staining. The white arrows indicate the actin aggregation (magnification × 800). The data are representative of three or five independent experiments, each yielding similar results , and b-actin was then detected using Western blot analysis with the corresponding antibodies; B. The myc-Akt vector was transfected into cells and followed by treatment with EGF (20 ng/ml) for 0.5 h; the protein expression of PLCg1, p-PLCg1 (Y783), p-PLCg1 (S1248), ERK, p-ERK1/2 (T202/Y204), MMP2, MMP3, Akt, myc, and b-actin was then detected using Western blot analysis with the corresponding antibodies; C. HA-PLCg1, HA-PLCg1 Y783A, and HA-PLCg1 S1248A vectors were transfected into cells, and the protein expression of PLCg1, p-PLCg1 (Y783), p-PLCg1 (S1248), ERK, p-ERK1/2 (T202/Y204), HA, and b-actin was detected using Western blot analysis with the corresponding antibodies; D. Cells were transfected with HA-PLCg1 and HA-PLCg1 Y783A vectors; this was followed by the gelatine zymography assay described in the Material and methods section; E. Cells were transfected with ShPLCg1 vector; this was followed by the Transwell assay described in the Material and methods section (***p < 0.001). The data are representative of three or five independent experiments, each yielding similar results
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The role of PLCg1 in metastasis of human gastric adenocarcinoma Figure 3C ). At the same time, HA-PLCg1 Y783A significantly reduced the expression of MMP2/9, as seen using gelatine zymography assay ( Figure 3D) , and the results of the Transwell assay demonstrated that the transfection of ShPLCg1 vector into the BGC-823 cells reduced the number of cell migrations ( Figure  3E , ***p < 0.001). Therefore, the data indicate the involvement of Akt in PLCg1-dependent migration of gastric adenocarcinoma cells, in which Akt triggers the PLCg/ERK/MMP pathway.
Discussion
In this study, we demonstrated that PLCg1 expression was related to the dissemination of gastric adenocarcinoma. Both the migration of cells and reorganization of the actin cytoskeleton partly depended on PLCg1 activation in the BGC-823 gastric adenocarcinoma cell line. This activation was mediated through Akt, an upstream of PLCg1 that triggered PLCg1/ERK/MMP pathway in the BGC-823 cells. Thus, PLCg1 activities may play an important role in the dissemination of gastric adenocarcinoma cells.
As one of switches that triggers cell migration, PLCg1 appears to be at the convergence point of various signalling pathways leading to cell cytoskeleton rearrangement and motility [24] . In line with previous studies of other tumors [8] [9] [10] 25] , the data from the tissue microarray and human tumor specimens demonstrate that PLCg1 expression is related to the dissemination of gastric adenocarcinoma cells. Furthermore, the disruption of PLCg1 led to the attenuation of cell migration and a decrease in both the number of cell membrane ruffles and the incidence of actin reorganization in BGC-823 cells. Thus, the migration of gastric adenocarcinoma cells partly depends on PLCg1 activation, and blocking PLCg1 could be a potential therapeutic approach to prevent gastric adenocarcinoma metastasis.
Although several lines of evidence indicated that the interaction between Akt and PLCg is involved in cell growth and migration [11, 12] , some studies argued against the regulatory mechanisms of the two signalling pathways in this process, whether upstream, downstream, or with each other. Browaeys-Poly et al. reported that Akt was known to phosphorylate its substrate, PLCg, and then to regulate the G2/M transition triggered by FGF receptors in MDA-MB-231 breast cancer cells [12] . However, Li et al. observed that Akt was phosphorylated to stimulate cell proliferation through the activated PLCg/PKCg/Src/PI3K pathway in EGF-stimulated rat and human conjunctival goblet cells [26] . Our data, indicating that Akt phosphorylates PLCg1 at the Y783 site and promotes cell migration, is consistent with Browaeys-Poly's study [12] . The different regulatory mechanisms of the two signalling pathways might be dependent on cellular context and type. Previous studies found that the PLCg1 activation was also regulated by phosphorylation at an additional serine/threonine site, even though PLCg1 was activated by tyrosine phosphorylation [27, 28] . Likewise, Akt simultaneously phosphorylates PLCg1 at the Y783 and S1248 sites in BGC-823 cells. We thus suggest that Akt, as an upstream, interacts with PLCg1, activates PLCg1 at the Y783 and S1248 sites in BGC-823 cells, and is involved in PLCg1-dependent migration. Further investigation into the role of p-PLCg1 (S1248) phosphorylated by Akt in gastric adenocarcinoma cell migration is underway.
In addition, ERK1/2, as a downstream effect of PLCg1, has been described as regulating MMP expression [29, 30] . The association of Ras-GRF1/2 with PLCg1 enables PLCg1 to be recruited to focal adhesions and is required for Ras signalling, ERK activation, and MMP-3 release downstream of IL-1 stimulation [29] . It was shown that PLCg1 could activate ERK1/2 through the PLCg1-PKCg-B-Raf pathway in VEGF-treated endothelial cells [30] . Consistent with previous studies, our data also indicate that PLCg1 activation is required for the phosphorylation of ERK. Combined with our result that the phosphorylation of ERK increases with the transfection of the myc-Akt vector in the presence or absence of EGF treatment, we suggest that Akt could mediate PLCg1 activation, which would trigger the PLCg1/ERK/MMP pathway to modulate the migration of BGC-823 cells.
In summary, in this study we have shown that PLCg1 activation is partly required for the migration of gastric adenocarcinoma cells. Moreover, this Akt--mediated activation triggers the PLCg1/ERK/MMP pathway in BGC-823 cells. Thus, the activation of PLCg1 and its interaction with Akt underline PLCg1 as a potential therapeutic target in gastric adenocarcinoma.
